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Abstract
Synaptotagmin I is a 65 kDa type 1 membrane glycoprotein found in secretory organelles that plays a key role in
regulated exocytosis. We have characterised two forms (long and short) of synaptotagmin I that are present in the bovine
adrenal medulla. The long form is a type I integral membrane protein which has two cytoplasmic C2 domains and
corresponds to the previously characterised full-length synaptotagmin I isoform. The short-form synaptotagmin I-vC2B
has the same structure in the lumenal and transmembrane sequences, but synaptotagmin I-vC2B is truncated such that it
only has a single cytoplasmic C2 domain. Analysis of synaptotagmin I-vC2B expression indicates that synaptotagmin
I-vC2B is preferentially expressed in the bovine adrenal medulla. However, it is absent from the dense core chromaffin
granules. Furthermore, when expressed in the rat pheochromocytoma cell line PC12 bovine synaptotagmin I-vC2B is
largely absent from dense core granules and synaptic-like microvesicles. Instead, indirect immunofluorescence microscopy
reveals the intracellular location of synaptotagmin I-vC2B to be the plasma membrane. ß 2002 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Synaptotagmins are a family of proteins compris-
ing at least 13 genes, all of which are type I integral
membrane proteins with two cytoplasmic C2 do-
mains [1^5]. The synaptic vesicle protein synaptotag-
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min I is the best characterised member of this family
and is a key component of the molecular machinery
which regulates the Ca2-dependent exocytosis of
synaptic vesicles [6]. The two C2 domains of synap-
totagmin I participate in a range of molecular inter-
actions thought to be involved in both exocytosis
and endocytic recycling. The membrane proximal
C2 domain (C2A) of synaptotagmin I interacts
with a subset of negatively charged phospholip-
ids [7,8] and with the soluble NEM sensitive fac-
tor (NSF) attachment protein (SNAP) receptor
(t-SNARE) syntaxin as a function of Ca2 binding
[9^11]. These interactions suggest that synaptotagmin
I may participate in the fusion of vesicles with the
plasma membrane, and indeed the C2A domain can
interact directly with the surface of lipid bilayers
after Ca2 binding [12,13]. In addition to these bind-
ing studies, there are more direct demonstrations of
the role of synaptotagmin I in synaptic vesicle exo-
cytosis, as mutants in organisms as diverse as Dro-
sophila, Caenorhabditis elegans and mice show de-
fects in evoked neurotransmitter release [14^17].
The membrane distal (C2B) domain also displays
Ca2-dependent interactions, namely an increased af-
¢nity for phosphatidylinositol-4,5-bisphosphate and
homo- and hetero-oligomerisation with other synap-
totagmin isoforms [18^22]. In addition the C2B do-
main also exhibits Ca2 independent activities. The
C2B domain binds to the L-isoform of SNAP
(L-SNAP), thereby forming a triple complex which
includes NSF [23] implying that the C2B domain
may act to adapt the general membrane fusion ma-
chinery to Ca2 regulation. The C2B domain may
also be involved in the recycling of synaptic vesicles
after fusion as it can bind to the AP2 clathrin adap-
tor complex [24,25], although the AP2 binding site is
not an internalisation motif per se [26]. Instead the
interaction between the C2B domain and AP2 is
thought to promote the nucleation of clathrin coated
vesicles at the plasma membrane after synaptic
vesicle exocytosis [27,28]. Indeed, the interaction of
synaptotagmin I with AP2 is promoted by peptides
which contain a tyrosine-based endocytosis motif
[27].
The exocytosis of dense core granules (DCG) from
bovine adrenal medulla chroma⁄n cells may also
involve synaptotagmin I. Synaptotagmin I is found
on the DCG of the adrenal medulla [29,30] and anti-
bodies speci¢c to the C2A domain block DCG re-
lease [31]. Moreover, soluble fragments of the C2A
domain or antibodies raised against that domain in-
hibit granule release in the rat pheochromocytoma
cell line PC12 [32], which shares many characteristics
with bovine adrenal medulla chroma⁄n cells. How-
ever, a mutant PC12 cell line which lacks synapto-
tagmin I can still undergo degranulation suggesting
that synaptotagmin I is not obligatory for fusion
[33]. Furthermore, the calcium requirement for
DCG release by chroma⁄n cells is lower than that
for synaptic vesicles and the rate of release much
slower [34,35]. These observations prompt the ques-
tion, does the exocytosis of DCG in chroma⁄n cells
require other synaptotagmins in addition to synapto-
tagmin I?
In this study we screened bovine adrenal medulla
cDNA libraries for novel synaptotagmin isoforms
that might be components of the regulated exocytic
apparatus in these cells. We describe two isoforms,
the ¢rst corresponding to the previously reported
bovine synaptotagmin I sequence [36]. The 5P end
of the second sequence, which we have designated
synaptotagmin I-vC2B, is identical to the published
bovine synaptotagmin I sequence, whereas its 3P end
is completely di¡erent (Fig. 1). Indeed, the synapto-
tagmin I-vC2B cDNA is predicted to encode a trun-
cation of synaptotagmin I that lacks the C-terminal
152 amino acids (aa), which include the majority of
the C2B domain. Analysis of the expression of syn-
aptotagmin I-vC2B indicates that it is preferentially
expressed in the adrenal medulla, implying a role in
DCG exocytosis. However, one consequence of the
truncated sequence of synaptotagmin I-vC2B is an
altered intracellular localisation. Subcellular fraction-
ation of adrenal medulla homogenates indicates that
synaptotagmin I-vC2B is absent from DCG. Fur-
thermore, when we analysed the expression of syn-
aptotagmin I-vC2B transfected into PC12 cells, syn-
aptotagmin I-vC2B is largely if not completely
absent from both regulatory secretory organelles
(RSOs) ^ the synaptic-like microvesicles (SLMV) ^
and DCG. Instead it is localised on the plasma mem-
brane.
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2. Materials and methods
2.1. Library screening and cloning of synaptotagmin
isoforms
Uni-directional, double-stranded cDNA was pre-
pared from bovine chroma⁄n cell mRNA, the 1.5^
4.5 kb size fraction cloned into Lambda ZAP, and
the cDNA packaged to produce six separate libraries
containing between 5U105 and 2U106 independent
clones each. A second size-fraction of 4.5 kb and
bigger cDNA was similarly cloned and packaged to
produce another library of about 106 independent
clones. Oligonucleotides were synthesised corre-
sponding to the human synaptotagmin I open read-
ing frame (ORF) sequence [37] which spanned posi-
tions 523^540 (GCTGCTGAACTGCCCGCC) in
the sense direction and positions 931^948
(GCCACCCACATCCATCTT) in the antisense di-
rection. These primers ampli¢ed a 425 bp fragment
in polymerase chain reactions (PCRs) with 10 ng of
human brain poly(A)-selected RNA. The PCR reac-
tion product was sub-cloned into Bluescript SK(3)
at the EcoRV site and the DNA sequence matched
the human synaptotagmin I sequence exactly [37].
5U105 plaques from two of the mid-range cDNA
and 2U105 from a lambda ZAP large-range cDNA
bovine libraries [38] were screened using this DNA as
a probe. Plaque lifts were hybridised under stringent
conditions with the 32P-labelled probe in 48% form-
amide, 4.8U SSC, 20 mM Tris^HCl (pH 7.6), 1U
Denhardt’s solution, 10% dextran sulphate, 0.1%
SDS at 42‡C. Filters were then washed with 0.2U
SSC, 0.1% SDS at 68‡C. Subsequent to cloning,
super-infection with VCSM13 helper bacteriophage
was used to excise the hybridisation positive Blue-
script SK(3) plasmid containing inserts [39]. Prelimi-
nary analysis by restriction mapping established that
the 13 ¢nal clones could be grouped into three di¡er-
ent classes corresponding to long, intermediate and
short forms. Only those clones corresponding to the
long and short forms were further characterised by
DNA sequencing. DNA sequencing demonstrated
that all these clones had a poly(A) tract at their
3P end, indicating that they are bona ¢de cDNAs.
The long form was identical to the published bovine
synaptotagmin I sequence [36], in contrast the short
form represented a truncation of the synaptotagmin I
ORF (synaptotagmin I-vC2B).
2.2. Reverse transcriptase^PCR (RT^PCR) analysis
of the bovine synaptotagmin isoforms
Antisense primers designed to hybridise at the
3P ends of speci¢c synaptotagmin isoforms were
used to produce single-stranded cDNA copies, using
as a template whole RNA isolated from both bovine
brain and adrenal medulla. The PCR primer for the
full-length synaptotagmin I isoform was at position
1921 (CAGGCTGGATGCTGCT) and for the syn-
aptotagmin I-vC2B isoform was at position 1660
(TGGCCCCAAAGTGAC). These cDNA tran-
scripts were in turn used in PCR reactions with a
sense oligonucleotide primer at position 9 (primer
5P-CATCTCAGCTGAACCCAC) speci¢c for the
common 5P sequence of both synaptotagmin iso-
forms and antisense primers speci¢c for either the
3P sequences of the full-length synaptotagmin I or
I-vC2B isoforms. The antisense PCR primer for syn-
aptotagmin I was at position 940 (primer 3PFL-AT-
CAGACAAGCCACCCAC) and, with the sense
primer I, produced a fragment 949 bp long. The
antisense PCR primer for synaptotagmin I-vC2B
was at position 1048 (primer 3PvC2B-GGGAAT-
GATCCAAGACC) and in combination with primer
I produced a fragment 1056 nucleotides long whose
sequence, when cloned, exactly matched that of syn-
aptotagmin I-vC2B.
2.3. Northern blot analysis
Total RNA was isolated from £ash-frozen adrenal
medullae as described [40]. RNA was denatured in
50.7% formamide and separated by electrophoresis in
1% agarose gels in 220 mM formaldehyde. Capillary
transfer to GeneScreen Plus membrane was per-
formed for 12 h in a bu¡er containing 25 mM
NaPO4 bu¡er, pH 6.5. The membrane was baked
at 65‡C for 2 h, pre-hybridised under standard con-
ditions [40], and then probed by incubation in the
same bu¡er containing DNA probe at approximately
106 cpm/ml, 108 cpm/Wg. The synaptotagmin I-vC2B
probe included nucleotides 2483^3417 of the I-vC2B
sequence and was labelled with [32P]dATP by ran-
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dom primer labelling or PCR ampli¢cation [40].
Samples were normalised by blotting with an 18S
rRNA-speci¢c probe, 18S-20 [41].
2.4. Primary antibodies
An isoform-common cytoplasmic domain rabbit
antiserum (729 Ab) was raised to a region held in
common by both the full-length synaptotagmin I and
the synaptotagmin I-vC2B isoforms. The antigen in
this case was a T7 gene 9 fusion protein with aa 74^
243 from the full-length synaptotagmin I which are
identical to the same region in synaptotagmin
I-vC2B. A full-length synaptotagmin I-speci¢c rabbit
polyclonal antiserum (I-FL Ab) was raised to the
C-terminal 122 aa fused to the T7 gene 9 protein
[42]. This region covers approximately half of the
C2B domain and the extreme C-terminus of the pro-
tein. A synaptotagmin I-vC2B-speci¢c rabbit poly-
clonal antiserum (I-vC2B Ab) was raised to a syn-
thetic peptide (CEKEEVRKTLAY), corresponding
to the C-terminal aa 267^276 of the synaptotagmin
I-vC2B isoform. The peptide was coupled to keyhole
limpet haemocyanin with m-maleimidobenzoyl-N-hy-
droxysuccinimide ester (Pierce Chemical Co.) via the
N-terminal cysteine residue. This antiserum shows no
immunoreactivity with the bacterially expressed
C-terminal 122 aa of the full-length synaptotagmin
I isoform. All synaptotagmin polyclonal antisera
were immunoa⁄nity puri¢ed by sequential adsorp-
tion and desorption to agarose-coupled glutathione-
S-transferase fusions with either the full-length syn-
aptotagmin I or I-vC2B cytoplasmic domains. The
common 729 and full-length speci¢c antisera were
used at 1/5000 dilution on immunoblots whereas
the I-vC2B antiserum was used at a 1/500 dilution.
The M2 FLAG epitope tag speci¢c monoclonal
antibody was purchased from Sigma. Synaptophysin
(p38) antiserum was raised against a GST-fusion
protein containing the carboxy-terminal domain of
the rat synaptophysin cDNA [43]. The chromogranin
A antiserum was a gift from Dr. D. Apps and the
synaptotagmin M48 monoclonal antibody [44] was a
gift from Dr. G. Schiavo.
2.5. Constructs
Expression vectors for the bovine full-length syn-
aptotagmin I and synaptotagmin I-vC2B isoforms
were generated by cloning their ORFs as BamHI/
XhoI fragments from the original Bluescript SK(3)
clones into the BamHI/SalI sites of pGW1 [45]. A
FLAG (DYKDDDDK) epitope tag was fused to
the C-terminus of synaptotagmin I-vC2B by PCR
ampli¢cation of the synaptotagmin I-vC2B ORF
cloned into pGW1 with the 5P primer ACTG-
CACCTCGGTTCTATCGATTG and the 3P primer
TATAAAGCTTATTTATCATCATCATCTTTGT-
AATCTATTAGAAATGCTAATGTTTT. The re-
sultant synaptotagmin I-vC2B-Flag PCR product
was cut with the enzymes EcoRI and HindIII and
cloned into the same sites of pRK34 [43].
2.6. Generation and sucrose gradient fractionation of
adrenal medulla homogenates
Adrenal medullae were homogenised in 300 mM
sucrose, 10 mM MOPS (pH 7.5), 1.0 mM phenyl-
methylsulfonyl £uoride, 0.1 mM N-tosyl-L-phenylala-
nine chloromethyl ketone, 0.1 mM p-aminobenzami-
dine, 2 Wg/ml pepstatin. Debris and nuclei were
removed by centrifugation in a JA20 rotor (Beck-
man) for 10 min at 3000 rpm to generate post nu-
clear supernatants used in either SDS^PAGE or sub-
sequent sucrose gradient fractionation. For
subsequent analysis by sucrose gradient fractiona-
tion, 3 ml of this supernatant was layered onto a
sucrose step gradient consisting of 3 ml each of 0.4,
0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, and 2.0 M sucrose
steps in 10 mM MOPS (pH 7.5) and centrifuged in
an SW28 rotor (Beckman) overnight at 20 000 rpm.
After centrifugation, 15 2-ml fractions were collected
from the top of the tube using an Autodensi-Flow
llC (Buchler Instruments).
2.7. Expression of synaptotagmin I-vC2B in PC12
cells
The day before transfection the PC12 cells were
plated to about 75% con£uency. On the day of trans-
fection a 9-cm dish was trypsinised, washed once in
DMEM plus sera, then twice in ice-cold HeBS bu¡er
(20 mM HEPES (pH 7.05), 137 mM NaCl, 5 mM
KCl, 0.7 mM Na2HPO4, 6 mM glucose) and the cells
resuspended into 250 Wl of HeBS in a 0.4-cm cuvette.
One Wg of DNA was added and the DNA/cell mix
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was given two pulses in a BioRad genepulser (400 V,
125 WF and in¢nite 6), cells were reseeded into a
9-cm dish in DMEM plus sera.
2.8. Ficoll gradient fractionation of PC12 cells
The procedure used was described by Cramer and
Cutler [46]. After transfection cells were grown under
normal conditions for 2 days. The cells were washed
twice with ice-cold homogenisation bu¡er (320 mM
sucrose, 10 mM HEPES (pH 7.4), 1 mM phenyl-
methylsulfonyl £uoride (HB)), washed into 1 ml
HB and homogenised on ice by nine passages
through a ball-bearing homogeniser, with a 0.012-
mm clearance (EMBL workshop). The cell homoge-
nate was spun in a microfuge at 11 000 rpm for 5 min
and 1 ml of the supernatant was layered onto 11 ml
of a 1^16% Ficoll linear gradient made in HB. The
gradients were centrifuged for 45 min at 35 000 rpm
in a SW40Ti rotor (Beckman), and fractionated into
0.5-ml fractions.
2.9. Glycerol gradient SLMV isolation
The procedure used was a modi¢cation of that
described by Desnos et al. [43,47]. Brie£y, the cells
were washed twice with and then resuspended in 1 ml
of bu¡er A (150 mM NaCl, 0.1 mM MgCl2, 1 mM
EGTA 1.0 mM phenylmethylsulfonyl £uoride and 10
mM HEPES, pH 7.4) and then homogenised (as
above) with a ball-bearing homogeniser. The homo-
genate was then centrifuged in a microfuge at 14 000
rpm for 15 min. One ml of the supernatant was
loaded onto the top of an 11-ml 5^25% glycerol (in
bu¡er A) gradient and centrifuged in a SW40Ti
(Beckman) rotor at 35 000 rpm for 2 h 50 min, and
fractionated into 0.5-ml fractions.
2.10. SDS^PAGE and immunoblotting
Adrenal medulla homogenates were separated by
SDS^PAGE on 7.5% gels, with 3-Wl samples of su-
crose gradient fractions loaded per lane. For Ficoll
and glycerol gradients of PC12 homogenates, 20 Wl
of each fraction was separated on 12% acrylamide
gels. All samples were loaded sequentially such that
fraction 1 corresponds to the top of the gradient.
Nitrocellulose replicas of the gels were made and
probed with the appropriate immunoa⁄nity-puri¢ed
rabbit antisera and HRP conjugated goat anti-rabbit
secondary antibody. Reactions were visualised with
the Amersham ECL detection system.
2.11. Immuno£uorescence confocal microscopy
Cells were ¢xed in 4% paraformaldehyde in PBS
and permeabilised in 0.2% saponin, 1% ¢sh skin gel-
atin in PBS. Cells were then stained with either the
anti-synaptotagmin M48 or the anti-FLAG epitope
tag M2 monoclonal antibodies followed by an anti-
mouse £uorescein-labelled secondary antibody (Jack-
son Laboratories). Antibody £uorescence was visual-
ised by confocal microscopy using an MRC1024
microscope (BioRad).
3. Results
3.1. Isolation of synaptotagmin I-vC2B
To identify synaptotagmin isoforms present in bo-
vine adrenal medulla chroma⁄n cells, we screened
bovine adrenal medulla libraries [38] with a fragment
of human synaptotagmin I cDNA, corresponding to
nucleotides 523^948 [37]. This region encodes aa
167^307 incorporating part of the ¢rst C2 domain
which is conserved throughout the synaptotagmin
family [1^5]. This analysis revealed three di¡erent
classes of synaptotagmin-like clones of which two
were analysed in detail (Figs. 1 and 2). Both have a
poly(A) tract at their 3P end, indicating that they are
bona ¢de cDNAs. Indeed, the ¢rst clone corresponds
to the previously characterised bovine synaptotagmin
I isoform [36]. However, whereas the 5P end of
the second clone cDNA designated synaptotagmin
I-vC2B is identical to the published bovine synapto-
tagmin I sequence, its 3P end is completely di¡erent
(Fig. 1). The synaptotagmin I-vC2B isoform may
arise from alternative splicing of the mRNA or be
the result of a partially processed message in which
an intron is retained. RT^PCR ampli¢cation of total
adrenal medulla RNA with a 5P primer speci¢c to the
sequence common to both isoforms in combination
with 3P primers speci¢c for each cDNA clone con-
¢rmed that each message is present in the adrenal
medulla (Fig. 2A and Section 2). Furthermore, the
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synaptotagmin I-vC2B-speci¢c RT^PCR product
was sequenced and matched the library cloned se-
quence exactly. Thus the synaptotagmin I-vC2B
cDNA, which has the longer 3P-untranslated tail, en-
codes a protein of 279 aa, that is identical to the
previously published synaptotagmin I sequence to
aa 270, but which diverges thereafter (Fig. 2B).
Like the full-length synaptotagmin I protein synap-
Fig. 1. Nucleotide sequence of synaptotagmin I-vC2B cDNA and predicted amino acid sequence. The amino acid sequence is shown
in single-letter code beneath the cDNA sequence. The DNA and amino acids sequences are numbered on the right. The GenBank ac-
cession number for synaptotagmin I-vC2B is AF239741.
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totagmin I-vC2B therefore possesses the membrane-
proximal C2A domain responsible for Ca2/phos-
pholipid/syntaxin binding, but the synaptotagmin
I-vC2B isoform lacks the distal C2B domain thought
to be involved in L-SNAP and, AP2 binding and the
Ca2-dependent association with phosphatidylinosi-
tol-4,5-bisphosphate and homo- and hetero-oligo-
merisation [18^22].
Fig. 2. Comparison of full-length synaptotagmin I and synaptotagmin I-vC2B cDNAs. (A) Schematic diagram of the full-length syn-
aptotagmin I and synaptotagmin I-vC2B genes. Restriction sites indicated: Bm, BamHI; B, BstXI; C, ClaI; I, EcoRI; V, EcoRV; N,
NcoI; P, PstI; S, SmaI; Sp, SpeI; X, XbaI. RT^PCR products from the full-length synaptotagmins I and I-vC2B are shown as PCR
5P/3PFL and PCR 5P/3PvC2B, respectively. 5P, 3PFL and 3PvC2B represent the primers used as described in Section 2. The dark bar
below each restriction map is the predicted protein, with the single transmembrane domain indicated as a box labelled ‘TM’. Number-
ing in the ¢gure refers to the nucleotide numbers. (B) Alignment of the full-length (FL) and synaptotagmin I-vC2B predicted protein
sequences. Periods indicate aa of identity with the top-most sequence. Bt refers to the Bos taurus synaptotagmin isoforms and Rn re-
fers to the Rattus norvegicus synaptotagmin I [52]. The two predicted C2 domains are italicised, while the transmembrane domain is
indicated by single underlining. Regions used for the production of isoform-speci¢c antisera are indicated by double underlining.
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3.2. Tissue distribution of the synaptotagmin I-vC2B
mRNA
The tissue distribution of synaptotagmin I-vC2B
isoform expression was analysed by probing North-
ern blots of £ash-frozen tissue samples with a DNA
probe speci¢c for the unique 3P sequence of this iso-
form (Fig. 3A). The synaptotagmin I-vC2B mRNA
(4.5 and 9 kb) was more abundant in the adrenal
medulla than in either brain cortex or stem (Fig.
3A, compare lane 1 with lanes 2 and 3), but was
absent from liver (Fig. 3A, lane 4) and lung (data
not shown). Synaptotagmin I-vC2B therefore repre-
sents a novel isoform that is preferentially expressed
in the adrenal medulla. This is in contrast to the
distribution of the full-length synaptotagmin I iso-
form, which is instead preferentially expressed in
the brain versus the adrenal medulla [48,49].
3.3. Analysis of synaptotagmin I-vC2B in adrenal
medullae homogenates
In order to examine the expression of the synap-
totagmin I-vC2B protein in the adrenal medulla, we
raised an antiserum speci¢c for synaptotagmin
I-vC2B, as well as an antiserum speci¢c for the
full-length synaptotagmin I isoform and a common
antiserum that recognises both isoforms. The com-
mon 729 antiserum was raised against a fusion pro-
tein containing aa 74^243 from the common N-ter-
minal sequences of the full-length synaptotagmin I
and synaptotagmin I-vC2B isoforms. In Western
blots of homogenised £ash-frozen adrenal medulla
the 729 antiserum recognised two di¡erent species
at 65 and 45 kDa (Fig. 3B, lane 1). The 65 kDa
species corresponds to the previously characterised
full-length synaptotagmin I isoform that is expressed
in the bovine adrenal medulla [29,30]. The presence
of a 45 kDa species is consistent with the expression
of synaptotagmin I-vC2B with its predicted shorter
cytoplasmic sequence. However, it has been reported
that in rat brain homogenates the full-length 65 kDa
synaptotagmin I molecule can be cleaved by pro-
teases C-terminal to the transmembrane domain to
generate a 40 kDa breakdown product comprising
the cytoplasmic region [50]. In order to demonstrate
that the 45 kDa band was indeed synaptotagmin
I-vC2B and not simply a breakdown product of
the full-length synaptotagmin I isoform, we used
antisera speci¢c for each isoform. Antiserum raised
against a fusion protein containing the C-terminal
122 aa of the full-length synaptotagmin I isoform
recognised a single species of 65 kDa (Fig. 3B, lane
2) consistent with the size of the mature glycosylated
full-length synaptotagmin I [36]. The full-length syn-
aptotagmin I-speci¢c antiserum did not recognise the
45 kDa species. This demonstrates that the 45 kDa
band is not simply a breakdown product of the full-
length synaptotagmin I as this would be predicted to
be recognised by the full-length speci¢c sera. A spe-
Fig. 3. Analysis of synaptotagmin I-vC2B expression in the bo-
vine adrenal medulla. (A) Northern blots of bovine tissues for
synaptotagmin I-vC2B. RNA was isolated, separated by elec-
trophoresis and probed as described in Section 2 using a specif-
ic probe to synaptotagmin I-vC2B. Lane 1, adrenal medulla;
lane 2, brain cortex; lane 3, brain stem; lane 4, liver. Samples
were normalised by blotting with an 18S rRNA-speci¢c probe,
18S-20 as described by [41], data not shown. (B) Immunoblots
of adrenal medulla homogenates probed with synaptotagmin
antibodies. Mono-speci¢c rabbit immunoa⁄nity-puri¢ed poly-
clonal antibodies were raised against regions unique to full-
length synaptotagmin I (Syt I FL) and to synaptotagmin
I-vC2B (Syt I-vC2B), as described in Section 2. In addition an
antiserum (729) was raised against a region common to both
synaptotagmin isoforms. These were used to probe Western
blots of total tissue homogenates derived from bovine adrenal
medullae as described in Section 2. Lane 1, 729 antiserum; lane
2, full-length synaptotagmin I-speci¢c antiserum; lane 3, synap-
totagmin I-vC2B-speci¢c antiserum.
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ci¢c synaptotagmin I-vC2B antiserum was raised
against a synthetic peptide comprising the C-terminal
9 aa unique to this molecule. Blots probed with this
antiserum labelled a 45 kDa protein (Fig. 3B, lane 3),
the same size as the smaller protein labelled with the
common 729 antiserum. Together, these data are
consistent with the expression of two di¡erent syn-
aptotagmin isoforms that have identical N-termini,
but diverge thereafter. We therefore conclude that
the full-length synaptotagmin I and synaptotagmin
I-vC2B isoforms are both expressed in the adrenal
medulla.
To determine the intracellular location of the two
synaptotagmin I variants, subcellular fractionation
was used. Bovine adrenal medulla homogenates
were centrifuged on sucrose gradients and fractions
analysed with the isoform-speci¢c antisera (Fig. 4).
The main immunoreactivity seen with the antisera to
the full-length synaptotagmin I isoform shows a peak
in fractions 10^12, paralleling the peak of chromo-
granin A within DCG. The additional chromogranin
A immunoreactivity at the top of the gradient is
soluble material within the load fractions. In addi-
tion, there is immunoreactivity for the full-length
synaptotagmin I isoform in light membrane fractions
which co-sediments with both the SLMV marker
synaptophysin and the transferrin receptor (fractions
8^9), marking the distribution of the plasma mem-
brane and of early endosomes. This broad distribu-
tion re£ects the presence of the full-length synapto-
tagmin I isoform in both DCGs and SLMV [50]. In
contrast, synaptotagmin I-vC2B immunoreactivity
was mainly found within only 2 fractions (8^9), in
the region in which membranes enriched in both syn-
aptophysin and transferrin receptor were located.
Unfortunately, an analysis of the intracellular local-
isation of synaptotagmin I-vC2B in bovine chromaf-
¢n cells by immuno£uorescence microscopy using the
I-vC2B-speci¢c anti-peptide antisera proved to be
unsuccessful. However, the fractionation data alone
indicate that the full-length synaptotagmin I isoform
largely co-fractionates with DCG whereas synapto-
tagmin I-vC2B is in a light membrane fraction dis-
tinct from the chroma⁄n granules.
3.4. Expression and analysis of synaptotagmin
I-vC2B in PC12 cells
The above data demonstrate that chroma⁄n cells
express the novel synaptotagmin I-vC2B isoform in a
light membrane fraction, but the identity of this frac-
tion was unclear. To pursue its identity, we turned to
another system; PC12 cells. This was for three rea-
sons. We anticipated an association of synaptotag-
min I-vC2B with regulated secretory organelles, and
so we wished to use a system in which the targeting
to both SLMV and DCG membranes has been ex-
tensively characterised. Indeed, we have recently
mapped a dileucine-like motif in the bovine full-
length synaptotagmin I isoform that promotes
SLMV targeting in PC12 cells [51]. Additionally, ex-
pression of synaptotagmin I-vC2B in PC12 cells
avoids any complications arising from the large num-
ber of di¡erent synaptotagmin genes and any of their
potential splicing products in adrenal medulla chro-
ma⁄n cells. In the absence of a complete catalogue
of synaptotagmin products in any given cell type, we
could never be absolutely sure that our antibodies
were only recognising a single gene product. By ex-
pressing a single cDNA and demonstrating the pres-
ence or absence of a single product, we could be sure
that our serum was only revealing the location of the
protein encoded by that particular mRNA. Finally,
by examining the location of an over-expressed pro-
Fig. 4. Sucrose gradient fractionation of adrenal medullae ho-
mogenates. Bovine adrenal medullae post-nuclear supernatants
were prepared and fractionated on sucrose gradients as de-
scribed in Section 2. Fractions were collected and Western blots
probed with immunoa⁄nity-puri¢ed antisera speci¢c to full-
length synaptotagmin I (indicated by Syt I FL) and synaptotag-
min I-vC2B (indicated by Syt I-vC2B). In addition fractions
were probed with antisera speci¢c to other marker proteins;
chromogranin A (indicated by CA), synaptophysin (indicated
by p38) and transferrin receptor (indicated by TfR). Chromo-
granin A in fractions 1^4 was released from granules during ho-
mogenisation; immunoreactivity found deeper in the gradient is
in granules.
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tein, we hoped to be able to use antibodies that rec-
ognise both forms to localise synaptotagmin I-vC2B
by immuno£uorescence, since our domain-speci¢c
antibodies had not provided useful immuno£uores-
cence data.
The cDNAs encoding the bovine full-length syn-
aptotagmin I and synaptotagmin I-vC2B isoforms
were cloned into an expression vector, PC12 cells
were transiently transfected with these two constructs
and their expression analysed 2 days after transfec-
tion. Previously we have described a Ficoll gradient
fractionation protocol used to analyse targeting to
exocytic compartments [46]. This procedure was
used to generally characterise the subcellular local-
isation of the two bovine synaptotagmin isoforms in
PC12 cells. We were unable to di¡erentiate between
the distribution of the endogenous rat synaptotagmin
I and the bovine full-length synaptotagmin I when
this was expressed in PC12 cells. The common 729
antiserum recognised a 65 kDa species in untrans-
fected PC12 cells, consistent with the endogenously
expressed rat synaptotagmin I isoform (Fig. 5A, lane
1). When the bovine full-length synaptotagmin I was
transfected into PC12 cells it was indistinguishable
from the endogenous rat synaptotagmin I as both
proteins migrated at 65 kDa (data not shown). How-
ever, due to the very high degree of sequence identity
(97%) between bovine and rat synaptotagmin I
[36,52], the two proteins should behave identically.
In contrast, we found no evidence for the endoge-
nous expression of a rat synaptotagmin I-vC2B in
PC12 cells. The synaptotagmin I-vC2B antibody
did not recognise a band of the predicted size and
synaptotagmin I-vC2B-speci¢c primers did not am-
plify a PC12 synaptotagmin I-vC2B cDNA (data not
shown). However, when bovine synaptotagmin
I-vC2B was expressed a single band with the same
molecular mass as that seen for synaptotagmin,
I-vC2B in chroma⁄n cells was seen in addition to
the endogenous rat synaptotagmin I (Fig. 5A, lane
2). A faint 45 kDa band was also present in untrans-
fected cells (Fig. 5A, lane 1), which might be a break-
down product of rat synaptotagmin I. However, the
amount of 45 kDa immunoreactive material was
much more intense in cells transfected with the syn-
aptotagmin I-vC2B cDNA. Since this band was de-
pendent on the expression of the cDNA encoding
synaptotagmin I-vC2B and the antibody recognises
both 65 and 45 kDa forms, we therefore conducted a
parallel comparison by subcellular fractionation of
the endogenous rat synaptotagmin I and the ex-
pressed bovine synaptotagmin I-vC2B in PC12 cells.
The highest concentration of rat synaptotagmin I
immunoreactivity in Ficoll gradients was found in
fractions 11^12 which correspond to the DCG peak
identi¢ed by labelling with [3H]dopamine prior to
homogenisation (Fig. 5B,C). In addition, a second
population of synaptotagmin I was found in lighter
fractions including those enriched in the SLMV
marker protein synaptophysin which peaks in frac-
tions 3^5 (Fig. 5C). This corresponds to synaptotag-
min I in the SLMV fraction, the analysis of which is
described below. These data conform with the distri-
bution of synaptotagmin I within PC12 cells found
by others [53]. In contrast, synaptotagmin I-vC2B in
PC12 cell homogenates was found in a light mem-
brane fraction, with a broad peak in fractions 4^8
(Fig. 5C). There was only a very limited proportion
of synaptotagmin I-vC2B immunoreactivity deeper
in the gradient, where [3H]dopamine-labelled DCGs
were found. Although synaptotagmin I-vC2B was
mainly in light fractions toward the top of the gra-
dient, the distribution was not identical with that of
the SLMV marker synaptophysin, the majority of
synaptotagmin I-vC2B instead being found slightly
deeper in the gradient. However, these data correlate
with the sucrose gradient fractionation of adrenal
medulla homogenates, in which synaptotagmin
I-vC2B is present in a light membrane fraction dis-
tinct from the chroma⁄n granules (Fig. 4).
The identity of the membrane fraction to which
synaptotagmin I-vC2B was targeted was unclear
from Ficoll gradients. To determine if synaptotagmin
I-vC2B was present in SLMVs, we used the glycerol
gradient procedure [43,47] to isolate SLMV from
cells transfected with this cDNA. We found that
the rat synaptotagmin I co-fractionated with the
SLMV marker protein synaptophysin, peaking in
fractions 10^11 (Fig. 5D). In contrast to endogenous
synaptotagmin I, much less immunoreactivity at 45
kDa was observed in these fractions. Furthermore
the level of the 45 kDa band relative to rat synapto-
tagmin I is signi¢cantly less than the level of synap-
totagmin I-vC2B relative to rat synaptotagmin I in
homogenates of transfected cells (Fig. 5A). Due to
the low level of immunoreactivity we cannot distin-
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guish between synaptotagmin I-vC2B and the break-
down product of rat synaptotagmin I on these gra-
dients, as we see no di¡erence between transfected
and untransfected cells (data not shown). The major-
ity of synaptotagmin I-vC2B was instead removed by
centrifugation of the homogenate prior to the glyc-
erol gradient (see Section 2). Therefore, even though
synaptotagmin I-vC2B is in a light membrane frac-
tion only a very limited proportion, if any, of syn-
aptotagmin I-vC2B is targeted to SLMV. Thus we
Fig. 5. Subcellular fractionation of synaptotagmin I-vC2B in PC12 cells. (A) Expression of synaptotagmin I-vC2B in PC12 cells. Ho-
mogenates of either mock (lane 1) or synaptotagmin I-vC2B (lane 2) transfected cells were probed with the common 729 antiserum.
(B,C) Ficoll gradient fractionation of synaptotagmin I-vC2B transfected PC12 cells. PC12 cell homogenates were fractionated on Fi-
coll gradients as described in Section 2. Fractions were collected and counted for [3H]dopamine labelling (B) and probed with either
the isoform common 729 immunoa⁄nity puri¢ed antiserum or a speci¢c synaptophysin antiserum. Synaptophysin is indicated by p38;
rat synaptotagmin I and bovine synaptotagmin I-vC2B are indicated by Syt I FL and Syt I-vC2B, respectively (C). Soluble material
is expected to be present in fraction 1, immunoreactivity and counts deeper in the gradient are associated with vesicular material. (D)
Glycerol gradient isolation of SLMV from of synaptotagmin I-vC2B transfected PC12 cells. SLMV were isolated on glycerol gradients
as described in Section 2. Fractions were collected and probed with either the isoform common 729 immunoa⁄nity-puri¢ed antiserum
or the synaptophysin-speci¢c antiserum (indicated by p38). Soluble material is expected to be present in fraction 1, while immunoreac-
tivity found deeper in the gradient is associated with vesicular material. Rat synaptotagmin I is indicated by Syt I FL and * indicates
immunoreactivity which may either correspond to bovine synaptotagmin I-vC2B or a breakdown product of rat synaptotagmin I.
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conclude that unlike rat synaptotagmin I, synapto-
tagmin I-vC2B is enriched in neither SLMV nor
DCG membranes.
To determine where synaptotagmin I-vC2B might
be, PC12 cells transfected with either bovine full-
length synaptotagmin I or synaptotagmin I-vC2B
were analysed by confocal immuno£uorescence mi-
croscopy. One advantage of analysing expression in
transiently transfected cells is that not all cells ex-
press the DNA. This allowed an easy comparison
of cells expressing the bovine synaptotagmins with
those that only express the endogenous rat synapto-
tagmin I. Staining with antibody M48 (which recog-
nises an epitope in the C2A domain) revealed that in
untransfected PC12 cells endogenous synaptotagmin
I was found in a punctate distribution characteristic
Fig. 6. Confocal immuno£uorescence microscopy of PC12 cells transfected with bovine full-length synaptotagmin I and synaptotagmin
I-vC2B. (A,B) PC12 cells transfected with bovine full-length synaptotagmin I. (C,D) PC12 cells transfected with bovine synaptotagmin
I-vC2B. (E) an untransfected PC12 cell. (F) PC12 cells transfected with synaptotagmin I-vC2B-FLAG. Cells were ¢xed, permeabilised
and stained with either the synaptotagmin I antibody M48 (A^E) or the M2 FLAG epitope tag-speci¢c antibody (F) in conjunction
with a £uorescein-conjugated secondary antibody as described in Section 2. Cells transfected with the expression vectors are upper-
most in each panel (A^D,F). Scale bar = 5 Wm.
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of DCG staining (Fig. 6E). In cells transfected with
full-length bovine synaptotagmin I, the bovine form
was superimposed onto the endogenous rat synapto-
tagmin I, accentuating the staining of these granular
structures in cells expressing either barely detectable
levels (Fig. 6A) or very high levels of the protein
(Fig. 6B). In marked contrast, when bovine synapto-
tagmin I-vC2B was expressed in PC12 cells it was
found on the plasma membrane (Fig. 6C,D). This
was not simply a consequence of over-expression,
as there was no increase in staining of DCGs and a
similar pattern was observed both in cells where syn-
aptotagmin I-vC2B was barely detectable (Fig. 6C)
and where expression was very high (Fig. 6D). Fi-
nally, to discriminate between the endogenous rat
synaptotagmin I and the bovine synaptotagmin
I-vC2B and therefore to con¢rm the plasma mem-
brane localisation, a FLAG (DYKDDDDK) epitope
tag was added to the C-terminus of synaptotagmin
I-vC2B. PC12 cells transfected with this construct
were stained with the FLAG epitope antibody M2
and analysed by immuno£uorescence microscopy.
The FLAG-tagged synaptotagmin I-vC2B was also
localised to the plasma membrane (Fig. 6F), con¢rm-
ing the plasma membrane localisation of synaptotag-
min I-vC2B. We therefore conclude that synaptotag-
min I-vC2B is found on the plasma membrane in
PC12 cells. Furthermore, due to the similarity be-
tween the RSOs in chroma⁄n and PC12 cells, we
predict that synaptotagmin I-vC2B will also be
present on the plasma membrane in bovine chromaf-
¢n cells.
4. Discussion
To date 13 members of the synaptotagmin family
have been described, all of which have two C2 do-
mains [1^5]. Here we describe two sequences, the ¢rst
of which corresponds to the previously characterised
bovine synaptotagmin I isoform [36], whereas the
second is a novel sequence that encodes synaptotag-
min I-vC2B. Synaptotagmin I-vC2B may be formed
by alternative splicing of the synaptotagmin I gene,
as the 5P end of the cloned synaptotagmin I-vC2B
cDNA is identical to that of the full-length synapto-
tagmin I, whereas the 3P ends are completely di¡er-
ent. Alternatively, synaptotagmin I-vC2B may result
from the retention of a normally spliced intron.
However, alternative splicing has been reported in
synaptotagmins I, IV, V and VII, which have splice
variants in which the transmembrane domain is re-
moved or altered [54,55]. Although synaptotagmin
I-vC2B is the only synaptotagmin isoform with a
single C2 domain, a protein expressed in pancreatic
L cells ^ granuphilin ^ which normally has two C2
domains also has a truncated isoform with a single
C2 domain [56].
The consequence of the di¡erent 3P sequences is to
generate proteins that have identical N-termini, but
di¡erent C-terminal cytoplasmic sequences. The I-
vC2B isoform has a unique cytoplasmic structure
in that it lacks the C-terminal 152 aa which include
the majority of the C2B domain. The functional con-
sequences of the di¡erent cytoplasmic sequences of
the two synaptotagmin isoforms are unclear, but one
obvious consequence is their distinct intracellular dis-
tributions. In bovine adrenal medulla chroma⁄n
cells the full-length synaptotagmin I is enriched in
DCG whereas synaptotagmin I-vC2B is localised to
a light membrane fraction. Analysis of the two bo-
vine isoforms in PC12 cells suggested that whereas
the full-length synaptotagmin I is present in both
SLMV and DCG, synaptotagmin I-vC2B is localised
to the plasma membrane. Given the similarities be-
tween chroma⁄n and PC12 cells it is likely that syn-
aptotagmin I-vC2B is also present on the plasma
membrane in chroma⁄n cells.
The di¡erent subcellular localisation of the bovine
synaptotagmin I isoforms indicates that the targeting
information in the cytoplasmic regions di¡ers be-
tween the two molecules. In PC12 cells SLMV are
formed directly from the plasma membrane and or
via an endocytic intermediate. The former route is
dependent upon the AP2 adaptor complex and clath-
rin [57] whereas the latter is sensitive to brefeldin A
(BFA) and dependent upon the AP3 adaptor com-
plex [58,59]. Full-length synaptotagmin I can interact
with AP2 via the C2B domain, which requires two
lysines, corresponding to Lys 326/Lys 327 in the bo-
vine sequence [24,25,27] and would be predicted to
utilise this pathway of SLMV targeting. Additional-
ly, we have described a dileucine-like motif (Met 417/
Leu 418) located within the extreme C-terminus of
the full-length synaptotagmin I isoform which is ca-
pable of promoting SLMV targeting in PC12 cells
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[51]. Targeting via this motif is BFA sensitive sug-
gesting that the full-length synaptotagmin I can also
utilise the AP3-dependent pathway of SLMV biogen-
esis [51]. Synaptotagmin I-vC2B has neither of the
motifs described for SLMV targeting, which is con-
sistent with our observation that little if any synap-
totagmin I-vC2B is present in SLMV. In addition,
the C-terminus of full-length synaptotagmin I con-
tains an endocytosis signal [26]. It is not known if
this signal is required for SLMV targeting, but it is
absent in synaptotagmin I-vC2B and may then cause
the accumulation of synaptotagmin I-vC2B at the
plasma membrane. In contrast to SLMV, DCG are
thought to bud directly from the trans-Golgi [60,61],
and no role has been proposed for either AP2 or
AP3 in this process. The sequence requirements for
DCG targeting of the full-length synaptotagmin I are
unknown, yet the absence of synaptotagmin I-vC2B
from DCG suggests that the C-terminal 152 aa of the
full-length synaptotagmin I also contain sequence in-
formation necessary for this process.
In addition to a¡ecting the subcellular localisation
of the two bovine synaptotagmin I isoforms, the dif-
ferent cytoplasmic sequences would be predicted to
a¡ect the functional properties of the two isoforms.
The absence of the C2B domain would reduce the
repertoire of molecular interactions in which synap-
totagmin I-vC2B could participate, with functional
consequences. Indeed, the Drosophila AD1 mutant
which lacks the C2B domain has a null phenotype
[15], presumably because interactions mediated by
the C2B domain are essential for synaptotagmin
function. Synaptotagmin I-vC2B would be unable
to bind to L-SNAP, or phosphatidylinositol-4,5-bis-
phosphate which bind to the C2B domain or partic-
ipate in Ca2-dependent and homo- and hetero-oloi-
gomerisation [18^22]. The absence of the C2B
domain would not preclude interactions via the
C2A domain, as the C2A domain alone can associate
with both negatively charged phospholipids and syn-
taxin as a function of Ca2 binding [8^11]. What
then is the function of synaptotagmin I-vC2B? The
expression of synaptotagmin I-vC2B by the chromaf-
¢n cells of the adrenal medulla suggests an involve-
ment in some aspect of their physiology. A recent
study may provide a clue to a potential function of
synaptotagmin I-vC2B. Expression of truncated
forms of synaptotagmin I lacking the C2B domain
inhibits clathrin mediated endocytosis [62]. Synapto-
tagmin I-vC2B would be predicted based on these
observations to similarly act as a negative regulator
of endocytosis. However, further work is required to
determine the function(s) of synaptotagmin I-vC2B
in chroma⁄n cells and whether it is indeed an inhib-
itor of endocytosis.
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